BioCentury on BioBusiness,
Emerging Company Profile
Regenesance developing anti-C6 mAbs for myasthenia gravis
Related tables, figures and sidebars
Regenesance: Stopping the MAC attack
Monday, October 29, 2012
B.V. is developing mAbs against complement 6 that may halt nerve damage
and provide a better safety profile than standard of care for the orphan
neurological disease myasthenia gravis. The mAbs are in lead optimization and
are expected to enter the clinic in 18 months.
Myasthenia gravis is an
autoimmune disorder characterized by a loss of signaling between nerve and
muscle cells that leads to muscle weakness. The disease can be life
threatening, as muscle weakness in the diaphragm can lead to breathing
difficulty and the need for respiratory support.
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2013 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
If you are a current subscriber, log in below or in the upper right corner of this
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]